Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21503429 | 0.83 | RIPK1 (0.34) | RIPK1 | |
| SCHEMBL19880763 | 0.82 | NR3C1 (0.36) | TSHR | |
| SCHEMBL14402848 | 0.82 | NR3C1 (0.36) | TSHR | |
| SCHEMBL23095177 | 0.81 | ALDH1A1 (0.36) | RIPK1 | |
| SCHEMBL3655056 | 0.81 | NOS2 (0.32) | — | |
| SCHEMBL22604930 | 0.80 | — | — | |
| SCHEMBL15185220 | 0.79 | PTGS2 (0.32) | TSHRRIPK1 | |
| SCHEMBL17586080 | 0.78 | RARB (0.32) | — | |
| SCHEMBL12450273 | 0.76 | GABRA1 (0.38) | TSHRRIPK1 | |
| SCHEMBL13166035 | 0.74 | TAS1R3 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10946000-B2 | Method for treating cancer with combination therapy | REDHILL BIOPHARMA LTD. (IL) | 2021-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10946000-B2 | Method for treating cancer with combination therapy | TPMT, KRAS, SDHA | TSHR 1700/4885RIPK1 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.